Related Experiment Videos
2-acetaminofluorene blocks cell cycle progression after hepatectomy by p21 induction and lack of cyclin E expression
C Trautwein1, M Will, S Kubicka
1Department of Gastroenterology & Hepatology, Medizinische Hochschule Hannover, Germany.
Abstract:
In the Solt-Faber model DENA and 2-Acetaminofluorene (AAF) treatment combined with hepatectomy induces hepatocellular carcinoma in rats. In this model AAF blocks proliferation of hepatocytes, while oval cells restore liver mass. Here we studied the molecular mechanism involved in blocking AAF-dependent cell cycle progression of hepatocytes. AAF inhibits cell proliferation of hepatocytes shown by the lack of Cyclin E expression before the G1/S phase restriction point. Immunfluorescence studies revealed that Cyclin E positive signals were restricted to oval cells, while hepatocytes remained negative. Additionally, AAF treatment induces strong nuclear p53 expression which is associated with increased p21 mRNA levels. Inhibition of active Cyclin/CdK (cyclin dependent kinase) complexes is reflected in AAF-treated animals by decreased RB expression and phosphorylation. The decrease in RB expression and phosphorylation, which is essential in triggering DNA synthesis and Cyclin A expression, leads to a deficiency in transcriptionally active E2F complex formation after hepatectomy. Thus, two molecular explanations are evident to account for AAF-dependent cell cycle progression of hepatocytes in vivo: first, induction of p53 expression which leads to higher p21 mRNA levels, and second, a lack of Cyclin E expression at the G1/S phase restriction point after hepatectomy.
Insights
Hepatocellular carcinoma development in rats involves 2-Acetaminofluorene (AAF) blocking hepatocyte proliferation. This study reveals AAF inhibits cell cycle progression via p53/p21 and lack of Cyclin E, preventing DNA synthesis.
Area of Science:
- Hepatology
- Molecular Biology
- Carcinogenesis
Background:
- The Solt-Faber model uses DENA and 2-Acetaminofluorene (AAF) with hepatectomy to induce hepatocellular carcinoma in rats.
- AAF treatment inhibits hepatocyte proliferation, while oval cells are involved in liver mass restoration.
Purpose of the Study:
- To investigate the molecular mechanisms by which AAF blocks hepatocyte cell cycle progression in vivo.
- To understand the role of specific cell cycle regulators in AAF-induced liver cancer.
Main Methods:
- Utilized the Solt-Faber rat model.
- Analyzed cell proliferation using immunofluorescence for Cyclin E.
- Assessed protein expression (p53, RB) and mRNA levels (p21) via molecular assays.
Main Results:
- AAF treatment inhibited hepatocyte proliferation, evidenced by absent Cyclin E in hepatocytes but present in oval cells.
- AAF induced strong nuclear p53 expression and increased p21 mRNA levels.
- Decreased RB expression and phosphorylation were observed, impairing E2F complex formation and DNA synthesis.
Conclusions:
- AAF-dependent cell cycle arrest in hepatocytes is mediated by two key mechanisms: p53 induction leading to elevated p21, and a lack of Cyclin E at the G1/S restriction point.
- These molecular events contribute to the development of hepatocellular carcinoma in the Solt-Faber model.